Delving into the Latest Updates on LAT-8881 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

Target

GHR

Mechanism

GHR agonists(Growth hormone receptor agonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Lumbar RadiculopathyRadicular Pain

Inactive Indication

Acute migraineDiabetic peripheral neuropathyNeuralgia, Postherpetic+ [2]

Originator Organization

Mesoestetic Sl

Active Organization

Lateral Pharma Pty Ltd.

Inactive Organization

Metabolic Pharmaceuticals Pty Ltd.

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC78H123N23O23S2

InChIKeyGVIYUKXRXPXMQM-BPXGDYAESA-N

CAS Registry221231-10-3

Gene Sequence

Sequence Code 86160

Source: *****

The study consists of two parts. Part A will evaluate the safety and tolerability of intravenous LAT8881 in healthy volunteers using an ascending dose schedule. Part B will evaluate the analgesic efficacy of a single intravenous dose of LAT8881, compared with placebo, in patients with lumbar radicular pain.
Healthy volunteers are not accepted for Part B.

Start Date17 May 2022

Sponsor / Collaborator

Lateral Pharma Pty Ltd.

[+1]

ACTRN12619001369112 / CompletedPhase 2

A proof of concept study of the efficacy and safety of oral LAT8881 in acute migraine

Start Date04 Oct 2019

Sponsor / Collaborator

Lateral Pharma Pty Ltd.

NCT04153409 / CompletedPhase 2

A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine

This is a randomised, placebo controlled, double blind, crossover proof of concept study to investigate the efficacy and safety of oral LAT8881 in acute migraine, with or without aura.

Start Date24 Sep 2019

Sponsor / Collaborator

Lateral Pharma Pty Ltd.

100 Clinical Results associated with LAT-8881

Login to view more data

100 Translational Medicine associated with LAT-8881

Login to view more data

100 Patents (Medical) associated with LAT-8881

Login to view more data

15

Literatures (Medical) associated with LAT-8881

16 Aug 2024·The Journal of Infectious Diseases

Harnessing Endogenous Peptide Compounds as Potential Therapeutics for Severe Influenza

Article

Author: Tate, Michelle D ; Ely, Lauren K ; Hodges, Christopher ; West, Alison C ; Harpur, Christopher M ; Lam, Maggie ; Le Page, Mélanie A ; Gearing, Andrew J

AbstractBackgroundExcessive pulmonary inflammation and damage are characteristic features of severe influenza virus infections. LAT8881 is a synthetic 16–amino acid cyclic peptide form of a naturally occurring C-terminal fragment of human growth hormone with therapeutic efficacy against influenza. Shorter linear peptides are typically easier to manufacture and formulate for delivery than larger cyclic peptides. A 6–amino acid linear peptide fragment of LAT8881, LAT9997, was investigated as a potential influenza therapy.MethodsLAT9997 was evaluated for its potential to limit disease in a preclinical mouse model of severe influenza infection.ResultsIntranasal treatment of mice with either LAT8881 or LAT9997 from day 1 following influenza infection significantly improved survival outcomes. Initiating LAT9997 treatment at the onset of severe disease also significantly improved disease severity. Greater disease resistance in LAT9997-treated mice correlated with reduced lung immunopathology, damage markers, vascular leak, and epithelial cell death. Treatment reduced viral loads, cytokines, and neutrophil infiltration in the airways yet maintained protective alveolar macrophages in a dose-dependent manner. Sequential trimming of N- and C-terminal amino acids from LAT9997 revealed a structure-activity relationship.ConclusionsThese findings provide preclinical evidence that therapeutic LAT9997 treatment limits viral burden and characteristic features of severe influenza, including hyperinflammation and lung damage.SummaryExcessive pulmonary inflammation and damage are characteristic features of severe influenza virus infections. LAT9997 is a linear peptide fragment derived from human growth hormone. This study provides preclinical evidence that therapeutic LAT9997 treatment limits viral burden, hyperinflammation, and lung damage.

01 Jan 2023·Clinical & Translational Immunology

Naturally derived cytokine peptides limit virus replication and severe disease during influenza A virus infection

Article

Author: Tate, Michelle D ; Harpur, Christopher M ; Hodges, Christopher ; Oseghale, Osezua ; Lam, Maggie ; West, Alison C ; Le Page, Mélanie A ; Gearing, Andrew J

AbstractObjectivesNovel host‐targeted therapeutics could treat severe influenza A virus (IAV) infections, with reduced risk of drug resistance. LAT8881 is a synthetic form of the naturally occurring C‐terminal fragment of human growth hormone. Acting independently of the growth hormone receptor, it can reduce inflammation‐induced damage and promote tissue repair in an animal model of osteoarthritis. LAT8881 has been assessed in clinical trials for the treatment of obesity and neuropathy and has an excellent safety profile. We investigated the potential for LAT8881, its metabolite LAT9991F and LAT7771 derived from prolactin, a growth hormone structural homologue, to treat severe IAV infection.MethodsLAT8881, LAT9991F and LAT7771 were evaluated for their effects on cell viability and IAV replication in vitro, as well as their potential to limit disease in a preclinical mouse model of severe IAV infection.ResultsIn vitro LAT8881 treatment enhanced cell viability, particularly in the presence of cytotoxic stress, which was countered by siRNA inhibition of host lanthionine synthetase C‐like proteins. Daily intranasal treatment of mice with LAT8881 or LAT9991F, but not LAT7771, from day 1 postinfection significantly improved influenza disease resistance, which was associated with reduced infectious viral loads, reduced pro‐inflammatory cytokines and increased abundance of protective alveolar macrophages. LAT8881 treatment in combination with the antiviral oseltamivir phosphate led to more pronounced reduction in markers of disease severity than treatment with either compound alone.ConclusionThese studies provide the first evidence identifying LAT8881 and LAT9991F as novel host‐protective therapies that improve survival, limit viral replication, reduce local inflammation and curtail tissue damage during severe IAV infection. Evaluation of LAT8881 and LAT9991F in other infectious and inflammatory conditions of the airways is warranted.

01 Jan 2015·Drug Testing and AnalysisQ2 · MEDICINE

Detection and in vitro metabolism of AOD9604

Q2 · MEDICINE

Article

Author: Cox, Holly D. ; Hughes, Cole M. ; Smeal, Stacy J. ; Cox, James E. ; Eichner, Daniel

AOD9604 is a peptide consisting of the C‐terminal fragment of human growth hormone from amino acids 177–191 with an additional tyrosine residue at the N‐terminus of the peptide. It is reported to mimic the lipolytic properties of growth hormone without the diabetogenic side effects. Therefore, AOD9604 may be used as a performance enhancing drug and is banned by the World Anti‐doping Agency (WADA). The peptide is available on several Internet websites and was recently identified in confiscated vials in the USA. To detect abuse of the peptide in athletes, a solid‐phase extraction method was validated in urine with a limit of detection of 50 pg/mL. The method has good linearity, precision (<20%), specificity and recovery (62%). Six potential metabolites of the peptide were identified after incubation of AOD9604 in serum and urine. Quantification of the metabolites in serum identified a single metabolite, consisting of amino acids CRSVEGSCG, which is significantly more stable than the other metabolites or the parent compound. Screening for AOD9604 and the stable metabolite may potentially allow an increased window of detection. Copyright © 2014 John Wiley & Sons, Ltd.

100 Deals associated with LAT-8881

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Obesity	Phase 2	AU	Metabolic Pharmaceuticals Pty Ltd.	-
Lumbar Radiculopathy	Phase 1	AU	Lateral Pharma Pty Ltd.	17 May 2022
Radicular Pain	Phase 1	AU	Lateral Pharma Pty Ltd.	17 May 2022
Acute migraine	Phase 1	AU	Lateral Pharma Pty Ltd.	24 Sep 2019
Diabetic peripheral neuropathy	Phase 1	AU	Lateral Pharma Pty Ltd.	09 Apr 2019
Diabetic peripheral neuropathy	Phase 1	GB	Lateral Pharma Pty Ltd.	09 Apr 2019
Neuralgia, Postherpetic	Phase 1	AU	Lateral Pharma Pty Ltd.	09 Apr 2019
Neuralgia, Postherpetic	Phase 1	GB	Lateral Pharma Pty Ltd.	09 Apr 2019
Osteoporosis	Phase 1	AU	-	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03865953 (CTgov)	Phase 2	Neuralgia, Postherpetic \| Diabetic peripheral neuropathy	53	LAT8881 (LAT8881)	wztcsgffyf(jpocgqkcnq) = pdbizqxefr plseaxndqw (iwnufankam, wjbjsprzzg - jqqxpsmzgk) View more	-	23 Apr 2021
				Placebo (Placebo)	wztcsgffyf(jpocgqkcnq) = rtgopoysve plseaxndqw (iwnufankam, jgavtmvrdj - vwxezehzat) View more
NCT04153409 (CTgov)	Phase 2	Acute migraine	21	LAT8881 (Active)	htvadsvvvx(kgjhtvjxam) = igkxbzdkfw kixaonurue (rkvblupgap, sjvljvjaxo - kcmdogxowe) View more	-	30 Mar 2021
				Placebo (Placebo)	htvadsvvvx(kgjhtvjxam) = mlslhjcicu kixaonurue (rkvblupgap, vutycdlopo - tnilmjzlnp) View more